GlucoTrack, Inc.
IGAP
NASDAQ Capital Market3.24
USD
+0.09
- -
CIK
0001506983
Return %
Stock
S&P500
1Y
-16.71
26.53
3Y
730.77
76.60
5Y
170.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David Malka
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 19 Ha'Yahalomim Street Ashdod Israel 6037607
- IPO Date
- Apr 25, 2013
- CIK
- 0001506983
- Website
- glucotrack.com
- Similar Companies
- Business
- GlucoTrack, Inc. specializes in the design, development, and commercialization of innovative medical devices focused on diabetes management, primarily through its implantable continuous blood glucose monitoring (CBGM) system. The company’s core products include the long-term implantable CBGM technology aimed at people with Type 1 and insulin-dependent Type 2 diabetes, featuring a sensor with longevity of up to three years and requiring minimal calibration. It also develops non-invasive glucose monitoring devices using a combination of ultrasound, electromagnetic, and thermal technologies for pain-free glucose measurement without blood draws. GlucoTrack's technologies target both patient and healthcare provider markets with products aimed at improving glucose monitoring accuracy, convenience, and patient quality of life globally. Founded in 2004 and headquartered in Rutherford, New Jersey, GlucoTrack operates internationally with ongoing clinical trials in countries including the United States and Australia. The company has recently advanced its product pipeline and clinical development by initiating a long-term, multicenter feasibility study to evaluate product safety and performance, and is preparing to submit an Investigational Device Exemption (IDE) to the U.S. FDA in Spring 2026 to initiate a U.S. pilot study. GlucoTrack expanded its clinical advisory team by appointing experts in pain management and medical technology to support additional applications like epidural glucose monitoring, extending its innovation beyond traditional glucose monitoring solutions. Significant recent corporate developments include a $20 million investment agreement with Sixth Borough Capital to accelerate commercialization efforts and clinical progress; a Note Purchase Agreement bringing $3 million in cash financing; and a strategic repurchase of Series A Warrants to strengthen its capital structure and reduce shareholder dilution. These financial moves underpin the company’s commitment to advancing clinical milestones and product enhancements. GlucoTrack also focuses on expanding its advisory boards with endocrinology and cardiology specialists to deepen engagement with the diabetes community. These actions collectively highlight the company’s efforts to solidify its market position and propel its novel CBGM technology toward commercial availability within the next year.
Integrity Applications, Inc. Implements Reverse Stock Split To Meet NASDAQ Initial Listing Requirements
Integrity Applications Announces the Appointment of David C. Klonoff, MD as Chair of Scientific Advisory Board
Integrity Applications Issues Shareholder Update Letter